CYPH

CYPH is not the cheap, profitable 9x-earnings stock its headline ratios suggest — it is the former Leap Therapeutics, a clinical-stage oncology company with no approved products and, in its own words, no revenue from product sales, that renamed itself Cypherpunk Technologies to pivot into a 'digital asset treasury strategy anchored by Zcash.' The only 'revenue' in the dataset is $1.50M from FY2021, with nothing recorded since. The reported FY2025 net income of $4.82M and the resulting 9.1 P/E are artifacts: operating income was -$41.1M (a -2,738% operating margin) and operating cash flow was -$43.9M, so the positive bottom line and the absurd 321.5% net margin must come from non-operating items (almost certainly mark-to-market gains on the newly accumulated ZEC and/or financing remeasurements), not from the business. The MD&A is explicit — net operating losses every year since inception in 2011, a $462.5M accumulated deficit, and an expectation to 'continue to incur significant expenses and have operating losses for at least the next several years.'

The balance sheet looks superficially strong — $154M equity, $163M assets, liabilities/equity of just 0.06x — but that strength is the recently raised capital now parked partly in Zcash, a volatile crypto asset, against $14.0M of actual cash that fell 70.3% YoY. Against a $43.9M annual operating burn, $14M of cash is well under a year of runway; management's claim of 12 months leans on the broader asset base and continued capital access. The filing concedes the company must 'raise additional capital' and 'may be unable to raise additional funds... when needed on favorable terms or at all.' Shares outstanding already ballooned 118.1% YoY, so existing holders are being diluted aggressively, and more issuance is the stated funding plan.